Health · 58 views
Cannabinoid pathways may offer targets for kidney disease as CKD affects 850 million people
Approximately 850 million people globally (9.1% of the world's population) have chronic kidney disease (CKD). The number of affected individuals has grown steadily during the past 20 years and is on track to continue rising.
AI Summary
A study from the Autonomous University of Aguascalientes in Mexico suggests that cannabinoid pathways could be a new therapeutic target for chronic kidney disease (CKD). CKD currently affects about 850 million people worldwide, a number that has risen steadily over the past two decades and is expected to keep increasing. Current treatments such as RAAS inhibitors and angiotensin receptor blockers can slow progression but do not halt the disease, and their effectiveness varies among patients. The researchers discuss the potential of targeting cannabinoid signaling in a paper published in Frontiers in Pharmacology.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Night-shift work linked to differences in heart structure and biomarkersContinue reading
- Lawyer calls for urgent review of Letby convictions after expert witness revelationsContinue reading
- Sanders’ ‘Medicare for All’ plan accrues more liberate and moderate support in CongressContinue reading
- US loses measles elimination status as knowledge gaps about disease and vaccine persistContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow